NCT00844233已完成1 期
A Single Arm Phase II Study of Neoadjuvant Therapy Using Irinotecan Bead in Patients With Resectable Liver Metastases From Colorectal Cancer
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 5
- 主要终点
- Tumour resectability at surgery
研究概览
简要总结
The objective of this study is to evaluate the safety and efficacy of Irinotecan Bead in the neoadjuvant treatment (i.e. the Irinotecan Bead is administered prior to surgery) of resectable liver metastases from colorectal cancer.
详细描述
The Primary Endpoint of this study is Tumour resectability at surgery. Secondary Endpoints:
- Safety assessed by SAE and AE monitoring (NCI CTCAE v3.0)
- Tumour response assessed by imaging (RECIST and necrosis)
- Viable residual tumour assessed by pathological evaluation of resected liver tissue.
- Recurrence (time and site) following resection
- Correlation of tumour response by imaging and pathology
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Presence of potentially resectable colorectal cancer liver metastases, with less than 60% liver tumour replacement. The consulting surgeon, according to local practice, will determine resectability.
- •Patients having undergone complete resection of the primary tumour without gross or microscopic evidence of residual disease (R0), or the primary tumour is considered R0 resectable at screening.
- •Age: 18-80 years.
- •ECOG Status ≤
- •No previous irinotecan-containing chemotherapy for advanced disease.
- •Previous chemotherapy is allowed (unless it contained irinotecan), but must have ended at least one month prior to study entry.
- •Presence of adequate contraception in fertile (M/F) patients. Pregnant or lactating women are excluded.
- •Absence of any other previous malignancy other than adequately treated in situ carcinoma of the cervix or non-melanoma skin cancer (unless there has been a disease-free interval of at least 10 years).
- •Patients should not have participated in another clinical trial with any investigational drug in the 30 days prior to enrolment.
- •Absence of:
- •Peripheral neuropathy (CTC > grade 1)
- •Uncontrolled congestive heart failure or angina pectoris, or hypertension or arrhythmia.
- •History of significant neurologic or psychiatric disorders
- •Active infection
- •Written informed consent according to ICH/EU GCP, and any applicable local, national or international regulations.
- •Patients with liver-dominant disease, defined as ≥80% of the tumour body burden confined to the liver. Unilobar disease, or bilobar disease suitable for treatment in a single chemoembolisation procedure, with a maximum of 4 lesions.
- •Hematologic function: WBC ≥3.0 x 10*9/L, platelets ≥100 x 10*9/L, Absolute neutrophil count > 1.5 x 10*9/l.
- •Adequate organ function as measured by:
- •Serum creatinine ≤2 x upper limit of normal (ULN).
- •Serum transaminases (AST & ALT) ≤5 x ULN.
- •Total bilirubin ≤1.5 x ULN.
- •Prothrombin time >50% of normal.
排除标准
- •Extrahepatic metastases constituting >20% of tumour body burden.
- •Contraindications to irinotecan:
- •Chronic inflammatory bowel disease and/or bowel obstruction.
- •History of severe hypersensitivity reactions to irinotecan hydrochloride trihydrate.
- •Severe bone marrow failure.
- •Concomitant use with St John's Wort.
- •Active bacterial, viral or fungal infection within 72 hours of study entry.
- •Allergy to contrast media that cannot be managed with standard care.
- •Any contraindication for hepatic embolisation procedures:
- •porto-systemic shunt.
- •hepatofugal blood flow.
- •severe atheromatosis.
- •Contraindication to hepatic artery catheterisation, such as a patient with severe peripheral vascular disease precluding catheterisation.
- •Other significant medical or surgical condition, or any medication or treatment regimens, that would place the patient at undue risk, that would preclude the safe use of chemoembolisation or would interfere with study participation.
研究组 & 干预措施
1
Experimental
Irinotecan Bead
干预措施: Irinotecan Bead (Device)
结局指标
主要结局
Tumour resectability at surgery
时间窗: 1 month
次要结局
- Safety assessed by SAE and AE monitoring (NCI CTCAE v3.0)(1 month)
研究者
研究点 (5)
Loading locations...
相似试验
进行中（未招募）
1 期
Clinical trial for the evaluation of a new drug (cabozantinib) treatment given before having kidney surgery in patients with kidney cancer that is advanced or has spreadocally Advanced or Metastatic Renal Cell CarcinomaMedDRA version: 20.0Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001201-93-ESFundación ONCOSUR50
招募中
2 期
A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach AdenocarcinomaAdvanced Gastric CancerNCT04799548Shanghai Zhongshan Hospital71
撤回
2 期
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast CancerBreast CancerNCT02215876Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
已完成
2 期
Neo-adjuvant Abiraterone Prostate StudyHigh Risk Localised Prostate CarcinomaNCT02160353Cancer Trials Ireland45
招募中
2 期
Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLCNon Small Cell Lung CancerNCT04875585Medical University Innsbruck33